These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 32202082)

  • 21. [PSA testing, biopsy and cancer and benign prostate hyperplasia in France].
    Tuppin P; Samson S; Fagot-Campagna A; Lukacs B; Alla F; Allemand H; Paccaud F; Thalabard JC; Vicaut E; Vidaud M; Millat B
    Prog Urol; 2014 Jul; 24(9):572-80. PubMed ID: 24975792
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ratio of free-to-total prostate specific antigen in serum cannot distinguish patients with prostate cancer from those with chronic inflammation of the prostate.
    Jung K; Meyer A; Lein M; Rudolph B; Schnorr D; Loening SA
    J Urol; 1998 May; 159(5):1595-8. PubMed ID: 9554361
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hyperthyroidism is not a significant risk of benign prostatic hyperplasia: A nationwide population-based study.
    Man KM; Chen KB; Chen HY; Chiang JH; Su YC; Man SS; Xie DD; Wang Y; Zhang ZQ; Bi LK; Zhang T; Yu DX; Chen WC
    Medicine (Baltimore); 2018 Sep; 97(39):e12459. PubMed ID: 30278528
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association of clinical benign prostate hyperplasia with prostate cancer incidence and mortality revisited: a nationwide cohort study of 3,009,258 men.
    Ørsted DD; Bojesen SE; Nielsen SF; Nordestgaard BG
    Eur Urol; 2011 Oct; 60(4):691-8. PubMed ID: 21705134
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The histological prevalence of prostatitis at Potchefstroom Hospital: a cross-sectional study.
    Prince Kasongo M; Philippa E; Fabienne WH; Marylyne Y; Behnazir M
    Pan Afr Med J; 2024; 47():8. PubMed ID: 38371643
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Influence of histological prostatitis on the clinical features of benign prostatic hyperplasia and prostate cancer].
    Zhang F; Si-Mu-Jiang-Abula A; Zhang LD
    Zhonghua Nan Ke Xue; 2014 Apr; 20(4):354-8. PubMed ID: 24873164
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diagnosis of chronic prostatitis by noninvasive methods in elderly patients with benign prostatic hyperplasia in China.
    Cao Q; Wu Y; Guan W; Zhu Y; Qi J; Xu D
    Andrologia; 2021 Jul; 53(6):e14055. PubMed ID: 33798278
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Histological inflammation and risk of subsequent prostate cancer among men with initially elevated serum prostate-specific antigen (PSA) concentration in the Finnish prostate cancer screening trial.
    Yli-Hemminki TH; Laurila M; Auvinen A; Määttänen L; Huhtala H; Tammela TL; Kujala PM
    BJU Int; 2013 Oct; 112(6):735-41. PubMed ID: 23746332
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Detection of prostate cancer and changes in prostate-specific antigen (PSA) six months after surgery for benign prostatic hyperplasia in patients with elevated PSA.
    Ozden C; Inal G; Adsan O; Yazici S; Ozturk B; Cetinkaya M
    Urol Int; 2003; 71(2):150-3. PubMed ID: 12890951
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [PSA in prostatic fluid].
    Lehmann K; Simmler F; Schmucki O; Hauri D
    Urologe A; 1994 May; 33(3):232-4. PubMed ID: 7519804
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of interleukin-8 in expressed prostatic secretion as a reliable biomarker of inflammation in benign prostatic hyperplasia.
    Liu L; Li Q; Han P; Li X; Zeng H; Zhu Y; Wei Q
    Urology; 2009 Aug; 74(2):340-4. PubMed ID: 19464042
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tissue S100/calgranulin expression and blood neutrophil-to-lymphocyte ratio (NLR) in prostatic disorders in dogs.
    Weinekötter J; Gurtner C; Protschka M; von Bomhard W; Böttcher D; Alber G; Kiefer I; Steiner JM; Seeger J; Heilmann RM
    BMC Vet Res; 2023 Nov; 19(1):234. PubMed ID: 37946179
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of chronic prostatitis on angiogenic activity and serum prostate specific antigen level in benign prostatic hyperplasia.
    Koseoglu RD; Erdemir F; Parlaktas BS; Filiz NO; Uluocak N; Etikan I
    Kaohsiung J Med Sci; 2007 Aug; 23(8):387-94. PubMed ID: 17666305
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Increased Risk of Benign Prostate Hyperplasia (BPH) in Patients with Gout: A Longitudinal Follow-Up Study Using a National Health Screening Cohort.
    Bang WJ; Choi HG; Kang HS; Kwon MJ; Kim JH; Kim JH; Kim SY
    Diagnostics (Basel); 2023 Dec; 14(1):. PubMed ID: 38201364
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Correlation of IPSS with IL-8 and COX-2 levels in patients with benign prostatic hyperplasia and prostatitis].
    Chen DA; Yang XZ; Zhang PH; Li GS; Chang DG
    Zhonghua Nan Ke Xue; 2013 Jun; 19(6):527-30. PubMed ID: 23862231
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association of chronic periodontitis with prostatic hyperplasia and prostatitis: A population-based cohort study in Taiwan.
    Fu E; Cheng CM; Chung CH; Lee WC; Chen WL; Sun GH; Chien WC
    J Periodontol; 2021 Jan; 92(1):72-86. PubMed ID: 32627845
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predictive Value of the Platelet-To-Lymphocyte Ratio in Diagnosis of Prostate Cancer.
    Yuksel OH; Urkmez A; Akan S; Yldirim C; Verit A
    Asian Pac J Cancer Prev; 2015; 16(15):6407-12. PubMed ID: 26434851
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Do men with prostate abnormalities (prostatitis/benign prostatic hyperplasia/prostate cancer) develop immunity to spermatozoa or seminal plasma?
    Hoover P; Naz RK
    Int J Androl; 2012 Aug; 35(4):608-15. PubMed ID: 22321000
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The effectiveness of the integrated approach to the treatment of chronic prostatitis, including in patients with benign prostatic hyperplasia].
    Zhiborev AB; Martov AG
    Urologiia; 2018 Oct; (4):81-87. PubMed ID: 30761794
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of 5α-reductase inhibitor and α-blocker therapy for benign prostatic hyperplasia on prostate cancer incidence and mortality.
    Van Rompay MI; Curtis Nickel J; Ranganathan G; Kantoff PW; Solomon KR; Lund JL; McKinlay JB
    BJU Int; 2019 Mar; 123(3):511-518. PubMed ID: 30216624
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.